Inventor · disambiguated record
Xin Yu
Also filed as: YU XIN
11 granted patents·13 pending applications·117 citations·filing 2009–2024
89Inventor score
Top patents by PatentIndex Score
24 records- 0196US9499596B2Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2012·Granted Nov 22, 2016·58 cites·17 claims
- 0295US10626174B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2016·Granted Apr 21, 2020·10 cites·22 claims
- 0395US10611836B2Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2016·Granted Apr 7, 2020·9 cites·12 claims
- 0494US9873740B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2014·Granted Jan 23, 2018·26 cites·13 claims
- 0587US2024417461A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2024·Application pending·0 cites
- 0685US10221133B2(Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancerUNIV RUTGERS·Filed 2016·Granted Mar 5, 2019·6 cites·11 claims
- 0785US2024166741A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2023·Application pending·0 cites
- 0883US10604481B2(Thio, oxo and seleno) semicarbazone complexes with zinc and their use for treating cancerUNIV RUTGERS·Filed 2019·Granted Mar 31, 2020·2 cites·7 claims
- 0981US2023098521A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2022·Application pending·0 cites
- 1077US10828288B2Hydrazone derivatives for the treatment of cancerUNIV RUTGERS·Filed 2016·Granted Nov 10, 2020·2 cites·14 claims
- 1177US10729671B2Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancerUNIV RUTGERS·Filed 2016·Granted Aug 4, 2020·2 cites·13 claims
- 1277US10604480B2(Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancerUNIV RUTGERS·Filed 2016·Granted Mar 31, 2020·2 cites·28 claims
- 1376US2021340253A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 1476US2021332132A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 1573US11390678B2Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2019·Granted Jul 19, 2022·0 cites·20 claims
- 1671US2020399366A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2020·Application pending·0 cites
- 1768US2009258013A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2009·Application pending·0 cites
- 1867US2024383910A1Small molecule btk degraders and methods of use thereofBAYLOR COLLEGE MEDICINE·Filed 2024·Application pending·0 cites
- 1964US2024150481A1Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumorsAMGEN INC·Filed 2024·Application pending·0 cites
- 2060US2017145093A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2016·Application pending·0 cites
- 2157US2024123073A1Novel ripk1 kinase targeting protacs and methods of use thereofBAYLOR COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 2252US11926672B2Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumorsAMGEN INC·Filed 2020·Granted Mar 12, 2024·0 cites·35 claims
- 2346US2021301020A1Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitorsAMGEN INC·Filed 2019·Application pending·0 cites
- 2445US2022018369A1Snap-on quick-release lock mechanism for unmanned aerial vehicleSICHUAN AOSSCI TECH CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xin Yu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →